A well-planned tech transfer is vital for the Drug Product (DP) manufacturing process to start off on the right foot. As a trusted CDMO partner, Samsung Biologics drives its clients’ development and commercialization efforts through a diverse toolkit and operational agility, accommodating projects of varying scale with speed and flexibility in ensuring a sterile final product. In this whitepaper, Brian Bayly, our Head of DP MSAT, presents how our end-to-end capability provides clients with the expertise, experience, and infrastructure to support aseptic production, all while maintaining top quality and full regulatory compliance.
A well-planned tech transfer is vital for the Drug Product (DP) manufacturing process to start off on the right foot. As a trusted CDMO partner, Samsung Biologics drives its clients’ development and commercialization efforts through a diverse toolkit and operational agility, accommodating projects of varying scale with speed and flexibility in ensuring a sterile final product. In this whitepaper, Brian Bayly, our Head of DP MSAT, presents how our end-to-end capability provides clients with the expertise, experience, and infrastructure to support aseptic production, all while maintaining top quality and full regulatory compliance.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article